Effect of blue light combined with probiotics on neonatal jaundice
蓝光联合益生菌治疗新生儿黄疸的效果观察

摘要

目的 对临床新生儿黄疸治疗中口服益生菌联合蓝光照射治疗效果进行探讨。方法 选择100例在我院进行治疗的新生儿黄疸患儿为研究对象，所有患儿均为2021年1月至2022年7月年入我院进行治疗患儿，所有患儿按照随机方式分为对照组（n=50）及观察组（n=50），利用蓝光照射对对照组患儿进行治疗，而观察则患儿在蓝光照射基础上给予口服双歧杆菌三联活菌散辅助治疗，对两组患者经治疗后的血清胆红素水平、临床疗效、退黄时间、住院时间等相关指标进行对比。结果 经治疗干预后，对照组患儿的治疗有效率达到74%，观察组患儿整体治疗有效率达到96%，两组相比较差异显著，P<0.05。且与对照组患儿相比较，观察组患儿经治疗后血清总胆红素、胆红素明显更低，差异显著，P<0.05。结论 在临床治疗新生儿黄疸过程中通过口服益生菌与蓝光照射联合方式能够充分发挥两者的协同效用，从多个途径加快患儿血清胆红素排泄，从而让患儿的退黄时间更快，具有极大临床推广价值。

Abstract

Objective To investigate the effect of oral probiotics combined with blue light irradiation in the treatment of neonatal jaundice.
Methods A total of 100 children with neonatal jaundice treated in our hospital were selected as research objects. All children were admitted to our hospital from January 2021 to July 2022 for treatment. All children were randomly divided into control group (n=50) and observation group (n=50), and the control group was treated with blue light irradiation. For observation, the children were given oral bifidobacterium triple viable powder adjuvant therapy based on blue light irradiation. After treatment, the serum bilirubin level, clinical efficacy, yellowing time, length of hospital stay and other related indicators were compared between the two groups.
Results After treatment intervention, the treatment effective rate of the control group reached 74%, the observation group of children overall treatment effective rate reached 96%, the two groups compared with significant difference, P<0.05. Compared with the control group, the serum total bilirubin and bilirubin in the observation group were significantly lower after treatment, the difference was significant (P<0.05).
Conclusion   In the clinical treatment of neonatal jaundice, the combination of oral probiotics and blue light irradiation can give full play to the synergistic effect of the two, accelerate the serum bilirubin excretion in children from multiple ways, so as to make the yellowing time of children faster, which has great clinical promotion value.